Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial, Ophthotech announced in a press release.
Sixty-four patients with wet age-related macular degeneration were enrolled in the randomized, dose-ranging, open-label, multicenter phase 2a safety trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab, Genentech). The treatment-naive patients were assigned to receive one of four dosing regimens.
“This uncontrolled clinical trial with a small sample size was not designed to detect a statistically significant difference between Zimura dose groups or to evaluate the efficacy of Zimura combination therapy with statistical significance,” Kourous A. Rezaei, MD, Ophthotech chief medical officer, said in the release.
After 6 months of treatment, the Zimura combination therapy was generally well tolerated, and the most frequently reported adverse events were related to the injection procedure, the release said.